These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037 [TBL] [Abstract][Full Text] [Related]
30. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433 [TBL] [Abstract][Full Text] [Related]
31. Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models. Passer BJ; Cheema T; Wu S; Wu CL; Rabkin SD; Martuza RL Cancer Gene Ther; 2013 Jan; 20(1):17-24. PubMed ID: 23138870 [TBL] [Abstract][Full Text] [Related]
32. Phenotypic characterization of mammosphere-forming cells from the human MA-11 breast carcinoma cell line. Rappa G; Lorico A Exp Cell Res; 2010 May; 316(9):1576-86. PubMed ID: 20074564 [TBL] [Abstract][Full Text] [Related]
33. Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Uchida H; Marzulli M; Nakano K; Goins WF; Chan J; Hong CS; Mazzacurati L; Yoo JY; Haseley A; Nakashima H; Baek H; Kwon H; Kumagai I; Kuroki M; Kaur B; Chiocca EA; Grandi P; Cohen JB; Glorioso JC Mol Ther; 2013 Mar; 21(3):561-9. PubMed ID: 23070115 [TBL] [Abstract][Full Text] [Related]
34. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Fukuhara H; Martuza RL; Rabkin SD; Ito Y; Todo T Clin Cancer Res; 2005 Nov; 11(21):7886-90. PubMed ID: 16278413 [TBL] [Abstract][Full Text] [Related]
35. The oncolytic herpes simplex virus vector, G47Δ, effectively targets tamoxifen-resistant breast cancer cells. Fan J; Jiang H; Cheng L; Liu R Oncol Rep; 2016 Mar; 35(3):1741-9. PubMed ID: 26718317 [TBL] [Abstract][Full Text] [Related]
36. Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. Liu R; Varghese S; Rabkin SD Cancer Res; 2005 Feb; 65(4):1532-40. PubMed ID: 15735042 [TBL] [Abstract][Full Text] [Related]
37. Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta. Wang J; Xu L; Zeng W; Hu P; Zeng M; Rabkin SD; Liu R Cancer Cell Int; 2014; 14(1):83. PubMed ID: 25360068 [TBL] [Abstract][Full Text] [Related]
38. A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus. Nigim F; Esaki S; Hood M; Lelic N; James MF; Ramesh V; Stemmer-Rachamimov A; Cahill DP; Brastianos PK; Rabkin SD; Martuza RL; Wakimoto H Neuro Oncol; 2016 Sep; 18(9):1278-87. PubMed ID: 26951380 [TBL] [Abstract][Full Text] [Related]
39. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265 [TBL] [Abstract][Full Text] [Related]
40. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer. Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]